AFFILIATIONS
1 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
6 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Massachusetts General Hospital, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
12 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
13 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
15 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
16 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
19 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
24 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
25 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
26 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
27 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
28 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington Medicine, Seattle, Washington, United States
29 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
30 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Introduction: Chronic myeloid leukemia (CML) more commonly affects older adults, thus its clinical course in adolescents and young adults (AYA) is incompletely characterized. CML in AYAs may exhibit more aggressive disease biology and occurs in a social context where treatment tolerance and adherence are challenging. We report clinical experience of CML in AYAs at three academic medical centers.
Methods: AYA patients (13.00-39.99y) diagnosed with CML between 2010-2025 were identified at Dana-Farber Cancer Institute (DFCI), Fred Hutchinson Cancer Center (FHCC), and Massachusetts General Hospital (MGH). The DFCI Hematologic Malignancies Data Repository and EMRs were used to ascertain cases and clinical data. Progression-free survival (PFS) was defined as time from diagnosis to accelerated phase (AP), blast phase (BP), or death; disease-specific event-free survival (Dis-EFS) as time from diagnosis to 6 mo BCR::ABL1>10%, 12 mo BCR::ABL1 >1%, loss of major molecular response (MMR), loss of complete cytogenetic response (CCyR), progression to AP/BP, or death; toxicity-inclusive EFS (Tox-EFS) as time to drug toxicity requiring therapy change combined with the Dis-EFS criteria; and overall survival (OS) as time from diagnosis until death from any cause. Predictors of EFS were assessed using univariable Cox regression.
Results: We identified 255 AYA CML patients (52% DFCI; 30% FHCC; 18% MGH) with median follow-up time 4.7 y. The median diagnosis age was 29 y (R:13-40; IQR:26-35); 61% were male. Patient-reported race/ethnicity was 83% White, 12% Hispanic/Latino, 8% Black, and 6% Asian. CML diagnosis was symptomatic (68%) or incidental (32%). At diagnosis, most (235, 93%) were in chronic phase (CP), and the rest were in AP (5, 2%) or BP (12, 5%). The median diagnostic hematologic parameters in CP were white cell count 149 K/mL (R:8-718), basophil %: 3.6 (R:0-20), blast %: 1.6 (R:0-19), hemoglobin 10.9 g/dL (R:5-18), and platelets 381 K/mL (R:13-2387); splenomegaly was noted in 68%. NGS at diagnosis was performed in 136 (58%); 85.3% had no mutations, and ASXL1 mutation was most frequent (8.1%). In CP and AP cohorts, additional cytogenetic abnormalities occurred in 14/240 (5%), and 9/14 (64%) were classified as high-risk.
For treatment in CP, 158 (67%) initially received a 2nd gen TKI (132 dasatinib, 17 nilotinib, 9 bosutinib); others received imatinib 30%, asciminib 2%, or another therapy 1%. Including all therapy lines, 8% received ponatinib and 20% received asciminib. By 12 mo, 82% achieved BCR::ABL1<1% (CCyR) (median time to CCyR 214d, R:125-377), and 56% achieved MMR (median time to MMR 378d, R:212-678). Deep molecular response (MR 4.5) was achieved in 45% patients. Treatment-free remission (TFR) was attempted in 35 patients after a median 4.5 y on therapy, with 20 sustaining TFR for median 18 mo. TKI-related toxicity occurred in 70% of patients and was the most common reason for first line therapy discontinuation or non-adherence. At last follow-up, 41% remain on initial TKI therapy, 24% remain on second line TKI, and 35% had received ≥3 therapies. Common toxicities were GI (27%), musculoskeletal (21%), fatigue (20%), and hematologic (18%).
Overall, 29/255 (11%) patients presented with, or progressed to, BP (15 myeloid; 13 B-lymphoid; 1 T-lymphoid); with mutations in ASXL1 (23.8%), IDH1 (9.5%), PHF6 (9.5%), and RUNX1 (9.5%) most common. In 17 patients progressing to BP from CP, ABL1 mutations were detected in 7/13 tested (T315I in 4/7).
Stem cell transplant was performed in 28 patients, including 15 (6.4%) diagnosed in CP (5 for resistance and 10 for AP/BP progression). 5-year OS was 97% (95%CI 95-100) for the CP cohort and 97% (95%CI: 94-99) overall. For the CP cohort only, 5-year PFS was 95% (95%CI: 92-98), 5-y Dis-EFS was 54% (95%CI: 47-62), and 5-y Tox-EFS was 39% (95%CI: 31-46). There was no association between age or ASXL1 mutation and EFS; first line treatment with a 2nd gen TKI improved Dis-EFS (HR= 0.52; 95%CI: 0.34-0.79; p=0.002) and Tox-EFS (HR= 0.43; 95%CI: 0.3-0.61; p<0.001) versus imatinib.
Conclusion: Across three tertiary cancer centers, AYA CML patients treated over the last 15 years achieved excellent responses and OS. Compared to imatinib, more potent 2nd gen TKIs were associated with improved EFS. However, suboptimal responses and treatment-related toxicity were common, driving frequent TKI switching. Future research is needed to determine if novel TKIs can improve treatment efficacy and tolerability in AYAs.